receptores glp 1 GLP-1 Receptor Agonist Services for Type 2 Diabetes and Obesity Drug Development Trends in the Development of

Second, contrary to CVOTs on GLP-1 RAs that included T2DM patients with established cardiovascular disease or at high cardiovascular risk, tirzepatide trials randomized T2DM patients irrespective of presence of prior cardiovascular disease or cardiovascular risk factors, a fact that may account for the very low number of recorded MACE, and possibly for type II errors

The appetite-stimulating effect of prednisone operates through different neurological pathways than hunger regulated by GLP-1 receptors

A sensitivity analysis was conducted and showed no differences related to sex or type 2 diabetes prior to MBS in the need for pharmacological therapy or the requirement for medication with a dose greater than or equal to 150 mg/day

Even modest weight loss of 5-10% can significantly improve metabolic health